TOP TIERMARKET NEWSWIRE
News & sentiment

PHARVARIS N V (PHVS) — News & AI sentiment

PHARVARIS N V (PHVS) news roundup. 6 stories in the past week, 7 over 30 days. Average 30-day sentiment is 63.6/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 17 sales totalling $20.4M — net selling of $20.4M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
6
avg sentiment 61.8/100
30d stories
7
avg sentiment 63.6/100
Insider net (90d)
$20.4M
0 buys · 17 sells
Congress (90d)
0
0 buys · 0 sells

PHVS news in the last 24 hours, 7 days, 30 days and 90 days

How much PHVS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowPHVS storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days661.8/100PHVS headlines →
Last 30 days763.6/100PHVS headlines →
Last 90 days5063.5/100PHVS headlines →

Latest stories on PHVS

2d ago
2d ago
Pharvaris rises after BofA upgrades to Buy
Seeking Alpha64 · neutralanalyst
5d ago
BofA upgrades Pharvaris stock rating on oral HAE treatment potential
Investing.com Analyst Ratings64 · neutralanalyst
5d ago
5d ago
6d ago
Oct 8
Sep 15
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data
Investing.com Analyst Ratings56 · neutralanalyst
Sep 14
Sep 10
Guggenheim raises Pharvaris stock price target on trial results
Investing.com Analyst Ratings61 · neutralanalyst
Sep 10
Sep 10
Sep 9
Sep 9
Sep 9
Sep 9
Sep 9
Sep 9
Wells Fargo raises Pharvaris stock price target on strong trial data
Investing.com Analyst Ratings63 · neutralanalyst
Sep 9
Sep 9
Sep 9
Citizens raises Pharvaris stock price target to $79 on HAE therapy
Investing.com Analyst Ratings61 · neutralanalyst
Sep 9
Sep 8
Oppenheimer raises Pharvaris stock price target on trial results
Investing.com Analyst Ratings63 · neutralanalyst
Sep 8
Sep 8
Open PHVS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →